Breast cancer, however, presents as a highly heterogeneous tumor type with relatively low immunogenicity, and only a select subset of patients exhibit a response to treatments involving immune checkpoint inhibitors such as PD-1 and PD-L1 [15]. The gene discussed is PDCD1; the disease is breast carcinoma.